Published in Toxins (Basel) on March 03, 2014
Multiple Ascending Dose (MDX1105-01) (Anti-PDL1) | NCT00729664
Safety Study of Anti-LAG-3 With and Without Anti-PD-1 in the Treatment of Solid Tumors | NCT01968109
Safety Study of IL-21/Anti-PD-1 Combination in the Treatment of Solid Tumors | NCT01629758
Ipilimumab With or Without Talimogene Laherparepvec in Unresected Melanoma | NCT01740297
Tremelimumab and CP-870,893 in Patients With Metastatic Melanoma | NCT01103635
Phase II, 2nd Line Melanoma - RAND Monotherapy | NCT00612664
A Phase 1 Study to Evaluate MEDI4736 in Combination With Tremelimumab | NCT01975831
Sipuleucel-T and Ipilimumab for Advanced Prostate Cancer | NCT01832870
First-Line Gemcitabine, Cisplatin + Ipilimumab for Metastatic Urothelial Carcinoma | NCT01524991
Ipilimumab and Imatinib Mesylate in Advanced Cancer | NCT01738139
Tremelimumab With Chemoembolization or Ablation for Liver Cancer | NCT01853618
Safety Study of IL-21/Ipilimumab Combination in the Treatment of Melanoma | NCT01489059
Ipilimumab and Lenalidomide in Advanced Cancer | NCT01750983
Doxycycline, Temozolomide and Ipilimumab in Melanoma | NCT01590082
HD IL-2 + Ipilimumab in Patients With Metastatic Melanoma (PROCLIVITY 02) | NCT01856023
Phase II Study of Abraxane Plus Ipilimumab in Patients With Metastatic Melanoma | NCT01827111
Neoadjuvant Combination Therapy With Ipilimumab and HighDose IFN-α2b for Melanoma | NCT01608594
Overview of current immunotherapeutic strategies for glioma. Immunotherapy (2015) 0.89
Autoimmune inner ear disease in a melanoma patient treated with pembrolizumab. J Immunother Cancer (2016) 0.84
Nonviral oncogenic antigens and the inflammatory signals driving early cancer development as targets for cancer immunoprevention. Clin Cancer Res (2015) 0.83
Improving cancer immunotherapy by targeting the STATe of MDSCs. Oncoimmunology (2016) 0.83
The efficacy and safety of immunotherapy in patients with advanced NSCLC: a systematic review and meta-analysis. Sci Rep (2016) 0.79
Update on targeted therapies for advanced non-small cell lung cancer: nivolumab in context. Ther Clin Risk Manag (2017) 0.75
Enhancing the safety of antibody-based immunomodulatory cancer therapy without compromising therapeutic benefit: Can we have our cake and eat it too? Expert Opin Biol Ther (2016) 0.75
Advances in Immunotherapy for Glioblastoma Multiforme. J Immunol Res (2017) 0.75
Harnessing immunosurveillance: current developments and future directions in cancer immunotherapy. Immunotargets Ther (2014) 0.75
Comparative beneficiary effects of immunotherapy against chemotherapy in patients with advanced NSCLC: Meta-analysis and systematic review. Oncol Lett (2017) 0.75
The immune checkpoint molecule V-set Ig domain-containing 4 is an independent prognostic factor for multiple myeloma. Oncotarget (2017) 0.75
Coinhibitory Receptor Expression and Immune Checkpoint Blockade: Maintaining a Balance in CD8(+) T Cell Responses to Chronic Viral Infections and Cancer. Front Immunol (2017) 0.75
Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med (2010) 67.34
Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N Engl J Med (2012) 52.99
Safety and activity of anti-PD-L1 antibody in patients with advanced cancer. N Engl J Med (2012) 35.24
Ipilimumab plus dacarbazine for previously untreated metastatic melanoma. N Engl J Med (2011) 26.90
Safety and tumor responses with lambrolizumab (anti-PD-1) in melanoma. N Engl J Med (2013) 18.08
Enhancement of antitumor immunity by CTLA-4 blockade. Science (1996) 17.94
Nivolumab plus ipilimumab in advanced melanoma. N Engl J Med (2013) 17.53
Lymphoproliferative disorders with early lethality in mice deficient in Ctla-4. Science (1995) 16.19
Loss of CTLA-4 leads to massive lymphoproliferation and fatal multiorgan tissue destruction, revealing a critical negative regulatory role of CTLA-4. Immunity (1995) 14.90
Immunologic self-tolerance maintained by CD25(+)CD4(+) regulatory T cells constitutively expressing cytotoxic T lymphocyte-associated antigen 4. J Exp Med (2000) 13.13
Development of lupus-like autoimmune diseases by disruption of the PD-1 gene encoding an ITIM motif-carrying immunoreceptor. Immunity (1999) 12.36
Intraepithelial CD8+ tumor-infiltrating lymphocytes and a high CD8+/regulatory T cell ratio are associated with favorable prognosis in ovarian cancer. Proc Natl Acad Sci U S A (2005) 10.89
Cancer regression and autoimmunity induced by cytotoxic T lymphocyte-associated antigen 4 blockade in patients with metastatic melanoma. Proc Natl Acad Sci U S A (2003) 10.71
Autoimmune dilated cardiomyopathy in PD-1 receptor-deficient mice. Science (2001) 8.31
Evidence for a tumoral immune resistance mechanism based on tryptophan degradation by indoleamine 2,3-dioxygenase. Nat Med (2003) 7.86
Enterocolitis in patients with cancer after antibody blockade of cytotoxic T-lymphocyte-associated antigen 4. J Clin Oncol (2006) 7.40
MHC class I molecules and KIRs in human history, health and survival. Nat Rev Immunol (2005) 6.98
Quantification of regulatory T cells enables the identification of high-risk breast cancer patients and those at risk of late relapse. J Clin Oncol (2006) 6.23
A randomized, double-blind, placebo-controlled, phase II study comparing the tolerability and efficacy of ipilimumab administered with or without prophylactic budesonide in patients with unresectable stage III or IV melanoma. Clin Cancer Res (2009) 5.99
Prognostic factors related to clinical response in patients with metastatic melanoma treated by CTL-associated antigen-4 blockade. Clin Cancer Res (2007) 5.51
Phase III randomized clinical trial comparing tremelimumab with standard-of-care chemotherapy in patients with advanced melanoma. J Clin Oncol (2013) 5.36
Tumor regression and autoimmunity in patients treated with cytotoxic T lymphocyte-associated antigen 4 blockade and interleukin 2: a phase I/II study. Ann Surg Oncol (2005) 5.36
The emerging role of CTLA-4 as an immune attenuator. Immunity (1997) 5.35
Management of immune-related adverse events and kinetics of response with ipilimumab. J Clin Oncol (2012) 5.23
Cancer immunosurveillance and immunoediting: the roles of immunity in suppressing tumor development and shaping tumor immunogenicity. Adv Immunol (2006) 4.98
Blockade of CTLA-4 on both effector and regulatory T cell compartments contributes to the antitumor activity of anti-CTLA-4 antibodies. J Exp Med (2009) 4.68
Anti-cytotoxic T-lymphocyte antigen-4 antibody: the first in an emerging class of immunomodulatory antibodies for cancer treatment. J Clin Oncol (2008) 4.23
Checkpoint blockade in cancer immunotherapy. Adv Immunol (2006) 4.09
Cytotoxic T lymphocyte-associated antigen 4 (CTLA-4) regulates the unfolding of autoimmune diabetes. J Exp Med (1998) 3.70
CTLA-4 blockade enhances clinical disease and cytokine production during experimental allergic encephalomyelitis. J Immunol (1996) 3.40
Ipilimumab (anti-CTLA4 antibody) causes regression of metastatic renal cell cancer associated with enteritis and hypophysitis. J Immunother (2007) 3.32
B7-H1/CD80 interaction is required for the induction and maintenance of peripheral T-cell tolerance. Blood (2010) 3.21
Phase 2 trial of single agent Ipilimumab (anti-CTLA-4) for locally advanced or metastatic pancreatic adenocarcinoma. J Immunother (2010) 3.06
Combination immunotherapy of primary prostate cancer in a transgenic mouse model using CTLA-4 blockade. Cancer Res (2000) 2.89
Intracellular trafficking of CTLA-4 and focal localization towards sites of TCR engagement. Immunity (1996) 2.74
Prognostic value of tumor-infiltrating CD4+ T-cell subpopulations in head and neck cancers. Clin Cancer Res (2006) 2.56
Phase I/II trial of tremelimumab in patients with metastatic melanoma. J Clin Oncol (2009) 2.53
Development of ipilimumab: contribution to a new paradigm for cancer immunotherapy. Semin Oncol (2010) 2.51
Ipilimumab alone or in combination with radiotherapy in metastatic castration-resistant prostate cancer: results from an open-label, multicenter phase I/II study. Ann Oncol (2013) 2.35
Immune modulation in cancer with antibodies. Annu Rev Med (2013) 2.23
CD25 blockade depletes and selectively reprograms regulatory T cells in concert with immunotherapy in cancer patients. Sci Transl Med (2012) 2.22
Immunotherapy of cancer in 2012. CA Cancer J Clin (2012) 2.12
Clinical experiences with anti-CD137 and anti-PD1 therapeutic antibodies. Semin Oncol (2010) 2.00
Clinical use of anti-CD25 antibody daclizumab to enhance immune responses to tumor antigen vaccination by targeting regulatory T cells. Ann N Y Acad Sci (2009) 1.96
High frequency of tumor-infiltrating FOXP3(+) regulatory T cells predicts improved survival in mismatch repair-proficient colorectal cancer patients. Int J Cancer (2010) 1.96
Ipilimumab and its toxicities: a multidisciplinary approach. Oncologist (2013) 1.91
At the bedside: CTLA-4- and PD-1-blocking antibodies in cancer immunotherapy. J Leukoc Biol (2013) 1.90
Transient T cell depletion causes regression of melanoma metastases. J Transl Med (2008) 1.61
OX40 is a potent immune-stimulating target in late-stage cancer patients. Cancer Res (2013) 1.57
Checkpoint blocking antibodies in cancer immunotherapy. FEBS Lett (2013) 1.54
Phase I study of the humanized anti-CD40 monoclonal antibody dacetuzumab in refractory or recurrent non-Hodgkin's lymphoma. J Clin Oncol (2009) 1.52
Cytokine-mediated disruption of lymphocyte trafficking, hemopoiesis, and induction of lymphopenia, anemia, and thrombocytopenia in anti-CD137-treated mice. J Immunol (2007) 1.52
Clinical development of the anti-CTLA-4 antibody tremelimumab. Semin Oncol (2010) 1.47
Expression and function of CTLA-4 in Th1 and Th2 cells. J Immunol (1998) 1.31
Specific blockade of CTLA-4/B7 interactions results in exacerbated clinical and histologic disease in an actively-induced model of experimental allergic encephalomyelitis. J Neuroimmunol (1997) 1.24
Phase II study of the anti-cytotoxic T-lymphocyte-associated antigen 4 monoclonal antibody, tremelimumab, in patients with refractory metastatic colorectal cancer. J Clin Oncol (2010) 1.24
New directions in cellular therapy of cancer: a summary of the summit on cellular therapy for cancer. J Transl Med (2012) 1.23
Activation rules: the two-signal theories of immune activation. Nat Rev Immunol (2002) 1.22
STAT3: a target to enhance antitumor immune response. Curr Top Microbiol Immunol (2011) 1.18
Ipilimumab-induced acute severe colitis treated by infliximab. Melanoma Res (2013) 1.16
Modulation of lymphocyte regulation for cancer therapy: a phase II trial of tremelimumab in advanced gastric and esophageal adenocarcinoma. Clin Cancer Res (2010) 1.14
Cancer immunotherapy. Mol Oncol (2012) 1.13
The immune system and cancer. Cancer Biother Radiopharm (2009) 1.11
A phase I multidose study of dacetuzumab (SGN-40; humanized anti-CD40 monoclonal antibody) in patients with multiple myeloma. Haematologica (2010) 1.10
The mechanisms of cancer immunoescape and development of overcoming strategies. Int J Hematol (2011) 1.05
Suppression of T-cell responses by tumor metabolites. Cancer Immunol Immunother (2011) 1.04
Mechanisms of CTLA-4-Ig in tolerance induction. Curr Pharm Des (2006) 1.03
A phase I study of dacetuzumab (SGN-40, a humanized anti-CD40 monoclonal antibody) in patients with chronic lymphocytic leukemia. Leuk Lymphoma (2010) 1.02
Update on immunologic therapy with anti-CTLA-4 antibodies in melanoma: identification of clinical and biological response patterns, immune-related adverse events, and their management. Semin Oncol (2010) 1.02
T regulatory cells in cancer: recent advances and therapeutic potential. Expert Opin Biol Ther (2010) 1.02
Drug of the year: programmed death-1 receptor/programmed death-1 ligand-1 receptor monoclonal antibodies. Eur J Cancer (2013) 1.01
Monoclonal antibody mechanisms of action in cancer. Immunol Res (2007) 0.98
Biology and clinical applications of CD40 in cancer treatment. Semin Oncol (2010) 0.96
Dacetuzumab, a humanized mAb against CD40 for the treatment of hematological malignancies. Curr Opin Investig Drugs (2009) 0.88
Ipilimumab (MDX-010) in the treatment of non-small cell lung cancer. Expert Opin Biol Ther (2012) 0.80